{"id":6488,"date":"2022-11-01T13:40:00","date_gmt":"2022-11-01T08:40:00","guid":{"rendered":"https:\/\/www.serenepharma.com\/?p=6488"},"modified":"2022-10-28T17:42:02","modified_gmt":"2022-10-28T12:42:02","slug":"bacille-calmette-guerin-bcg-ning-mushak-bolmagan-invaziv-siydik-pufagi-saratoni-mbisps-uchun-standart-dozalariga-nisbatan-bacille-calmette-guerin-bcg-ning-past-dozali-samarador","status":"publish","type":"post","link":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/bacille-calmette-guerin-bcg-ning-mushak-bolmagan-invaziv-siydik-pufagi-saratoni-mbisps-uchun-standart-dozalariga-nisbatan-bacille-calmette-guerin-bcg-ning-past-dozali-samarador\/","title":{"rendered":"Bacille Calmette\u2013Gu\u00e9rin (BCG) ning mushak bo’lmagan invaziv siydik pufagi saratoni (MBISPS) uchun standart dozalariga nisbatan bacille Calmette\u2013Gu\u00e9rin (BCG) ning past dozali samaradorligi va xavfsizligi."},"content":{"rendered":"\n

Havola: <\/strong>Choi, S. va boshq., past dozalar va Kalmett-Geren bacillusning mushaksiz invaziv siydik pufagi saratoni uchun standart dozalari: randomizatsiyalangan nazorat ostida o’tkazilgan tadqiqotlarni tizimli ko’rib chiqish va meta\u2013tahlil, Investig<\/em> <\/em>Clin<\/em> <\/em>Urol<\/em>.<\/em> <\/em>2022 <\/em>Mar<\/em>;63(2):140-150. <\/em>Doi<\/em>: 10.4111\/<\/em>icu<\/em>.20210340.<\/em><\/p>\n\n\n\n

Kirish<\/h3>\n\n\n\n

Quviqning mushak bo’lmagan invaziv siydik pufagi saratoni (MBISPS) ning qaytalanish darajasi va rivojlanishini baholash uchun bir nechta tadqiqotlar o’tkazildi. Bacille Calmette\u2013Gu\u00e9rin (BCG)  intravezikal joylashuvi bu bemorlarda kimyoterapiya dorilariga qaraganda ancha samarali ekanligini ko’rsatdi. Shu bilan birga, nojo’ya ta’sirlar (NT) tashvishlanishning asosiy sababi bo’lib, terapiyani bekor qilishga olib keldi. Dunyo bo’ylab BCG etishmovchiligi mavjud va past dozali BCG eng yaxshi variant bo’lishi mumkin.<\/p>\n\n\n\n

Maqsad<\/h3>\n\n\n\n

Ushbu meta-tahlil MBISPS bemorlarda past dozali BCG samaradorligini saqlab turishi va NT ni kamaytirishi mumkinligini baholadi.<\/p>\n\n\n\n

Usul<\/h3>\n\n\n\n

Tadqiqot dizayni<\/strong><\/h4>\n\n\n\n
  • Randomizatsiyalangan nazorat ostida o’tkazilgan tadqiqotlarni (RNT) muntazam ravishda ko’rib chiqish va meta-tahlil qilish.<\/li><\/ul>\n\n\n\n

    Davolash strategiyasi<\/strong><\/h4>\n\n\n\n
    • Tegishli RNT PubMed, Embase, Cochrane library, CINAHL, Web of Science va Scopus ma’lumotlar bazalarida adabiyotlarni sinchkovlik bilan qidirgandan so’ng aniqlandi.<\/li>
    • Hammasi bo’lib 9 RCT (n=1217) kiritilgan va past va standart dozalar uchun 95% ishonch oralig’i (CI) bilan koeffitsientlar nisbati (KN) taqqoslangan.<\/li>
    • Kam doz BCG ning standart dozasiga nisbatan past BCG hajmi sifatida aniqlandi (Armand Frappier, 120 mg; Connot, 81 mg; Daniya 1331, 120 mg; o’zgartirilgan Daniya 1331, 120 mg; Tokio 172, 80 mg).<\/li><\/ul>\n\n\n\n

      Oxirgi nuqtalar<\/strong><\/h4>\n\n\n\n
      • Relaps darajasi<\/li>
      • O’smaning rivojlanishi<\/li>
      • Saratonga xos omon qolish darajasi (SXO)<\/li>
      • Umumiy omon qolish (UO)<\/li>
      • NT<\/li>
      • Davolashni bekor qilish chastotasi<\/li><\/ul>\n\n\n\n

        Natijalar<\/h3>\n\n\n\n
        • Kam dozali guruhda relaps darajasi yuqori bo’lgan,<\/li>
        • Shu bilan birga, o’simta, SXO va UO ning rivojlanishi 1-rasmda ko’rsatilgandek guruhlarda bir xil edi.<\/li><\/ul>\n\n\n\n

          1-rasm. Oxirgi nuqtalarni taqqoslash<\/p>\n\n\n

          \n
          \"\"<\/figure>\n<\/div>\n\n\n
          • Past dozali guruhda NT chastotasi past edi (osh 0,41; 95% CI 0,28-0,62; p<0,0001).<\/li>
          • 1-rasmda ko’rsatilgandek, past dozali guruhda davolanishni to’xtatish darajasi ham sezilarli darajada past edi.<\/li><\/ul>\n\n\n\n

            Xulosa<\/strong><\/h3>\n\n\n\n
            • BCG ning past dozalari BCG ning standart dozalariga qaraganda yuqori takrorlanish tezligiga ega bo’lsa-da, o’smaning rivojlanishi, saratonga xos omon qolish darajasi va umumiy omon qolish dozalari o’rtasida bir xil edi.<\/li>
            • BCG ning past dozali xavfsizlik profili standart dozadan yaxshiroq edi, buni yon ta’sirining past darajasi va olib tashlashning past darajasi ko’rsatadi.<\/li>
            • BCG ning past dozalari hozirgi BCG etishmovchiligi stsenariysida haqiqiy alternativa bo’lishi mumkin.<\/li><\/ul>\n","protected":false},"excerpt":{"rendered":"

              Havola: Choi, S. va boshq., past dozalar va Kalmett-Geren bacillusning mushaksiz invaziv siydik pufagi saratoni uchun standart dozalari: randomizatsiyalangan nazorat ostida o’tkazilgan tadqiqotlarni tizimli ko’rib chiqish va meta\u2013tahlil, Investig Clin Urol. 2022 Mar;63(2):140-150. Doi: 10.4111\/icu.20210340. Kirish Quviqning mushak bo’lmagan invaziv siydik pufagi saratoni (MBISPS) ning qaytalanish darajasi va rivojlanishini baholash uchun bir nechta tadqiqotlar o’tkazildi. Bacille…<\/p>\n","protected":false},"author":1,"featured_media":6451,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"rs_blank_template":"","rs_page_bg_color":"","slide_template_v7":"","inline_featured_image":false,"footnotes":""},"categories":[141],"tags":[173],"class_list":["post-6488","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gazetauz","tag-onkologiya"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t